Exclusively focused on translational aspects of drug delivery, this journal provides a unique forum for publication of high-quality research.

Drug Delivery and Translational Research publishes research focused on such topics as designing and developing novel drug delivery systems, with a focus on their application to disease conditions; preclinical and clinical data related to drug delivery systems; short-term and long-term biocompatibility of drug delivery systems, host response; biomaterials with growth factors for stem-cell differentiation in regenerative medicine and tissue engineering; image-guided drug therapy; nanomedicine; devices for drug delivery and drug/device combination products.

In addition to original full-length papers, communications, and reviews, the journal includes editorials, reports of future meetings, research highlights, and announcements pertaining to activities of the Controlled Release Society.

Drug Delivery and Translational Research publishes six issues a year.

  • Accepted by ISI in SCIE, Biosis Previews and Biological Abstracts

    Explores the effect in different disease conditions of rationally developed, effective delivery systems
  • Focuses on high-quality research on the development of novel drug delivery systems
  • Presents full-length papers, communications, and reviews, editorials and more

Journal information

Editor-in-Chief
  • Maria Jose Alonso
Publishing model
Hybrid. Learn about publishing OA with us

Journal metrics

2.664 (2019)
Impact factor
3.041 (2019)
Five year impact factor
57 days
Submission to first decision
153 days
Submission to acceptance
103,623 (2019)
Downloads

Latest articles

This journal has 66 open access articles

Journal updates

  • COVID-19 and impact on peer review

    As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times.  Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.

  • Featured article for October 2020 issue

    Read the featured article from the October 2020 issue!


    New Content ItemSummary: The effect of local anesthetics, particularly those which are hydrophilic, such as tetrodotoxin (TTX), is impeded by tissue barriers that restrict access to individual nerve cells. Insonation has been used to disrupt vascular and cell membranes, which can facilitate transport of substances across biological barriers. Using an in vivo model of local anesthetic delivery, we investigated the effect of acoustic intensity on insonation-mediated delivery of local anesthetics to the peripheral nerve. We found that insonation at acoustic intensity greater than 0.5 W/cm2 was capable of enhancing TTX delivery to the peripheral nerve but not bupivacaine, a more hydrophobic local anesthetic. The finding here suggests that the effect of insonation on local drug delivery to the peripheral nerve depends on the hydrophilic/hydrophobic balance of the drug.

  • Featured Article: August 2020

    New Content ItemRead the article!

    Summary: Sorafenib, a first-line drug for advanced liver cancer, exhibits low and inconsistent oral bioavailability due primarily to its poor aqueous solubility, extensive first-pass metabolism and high level drug efflux by P-gp. Administration of sorafenib at high doses, necessary for meaningful therapeutic action, increases the intensity of associated side effects. Therefore, efforts were undertaken to develop supersaturated Type-III self-emulsifying delivery system for efficient and safe delivery of sorafenib, capitalizing the ease of preparation, biocompatibility, biodegradability, ability to bypass first-pass metabolism, high drug loading capacity, colloidal stability for long-term storage, and excellent scalability. Promising outcomes in diverse experimental studies corroborate immense potential of the system in augmenting the chemotherapeutic efficacy of sorafenib while minimizing safety concern.

    This paper was selected as the best paper of the August 2020 issue by the Guest Editors and Main Editors. This article will be Free-to-Access until 24 September, 2020.

  • Best article from the June 2020 special issue on Nanomedicines

    New Content ItemRead the best article from the June 2020 issue!

    Summary: Bevacizumab is a monoclonal antibody that specifically inactivates VEGF-A, resulting in a decrease of the development of tumor blood vessels and its growth. Currently, it is employed in the treatment of different types of tumors, particularly colorectal cancer. As for other biologicals, the benefits of bevacizumab are limited by a low capability to penetrate into the tumors that, in addition, may increase the risk of acquiring resistance. In this work, the effect of the nanoencapsulation of bevacizumab (in human serum albumin nanoparticles) was evaluated on a xenograft model of human colorectal cancer.   

    The resulting nanoparticles demonstrated to be more effective in decreasing the glycolysis and metabolic tumor volume than the conventional treatment. This improvement was associated with a significantly higher accumulation of the monoclonal antibody in the tumor tissues when nanoencapsulated in human serum albumin nanoparticles.

    This article was selected as the best article of the Nanomedicines Special Issue by the CRS Nanomedicine and Nanoscale Delivery Focus Group.

View all updates

Societies, partners and affiliations

Subscribe

eJournal
$99.00
Note this is only the net price. Taxes will be calculated during checkout.
  • Immediate online access with complete access to all articles
  • Downloadable in PDF format
  • Subscription expires 12/31/2020

About this journal

Electronic ISSN
2190-3948
Print ISSN
2190-393X
Abstracted and indexed in
  1. CNKI
  2. Chemical Abstracts Service (CAS)
  3. Dimensions
  4. EBSCO Discovery Service
  5. EMBASE
  6. Google Scholar
  7. Institute of Scientific and Technical Information of China
  8. Japanese Science and Technology Agency (JST)
  9. Journal Citation Reports/Science Edition
  10. Medline
  11. Meta
  12. Naver
  13. OCLC WorldCat Discovery Service
  14. ProQuest-ExLibris Primo
  15. ProQuest-ExLibris Summon
  16. Reaxys
  17. SCImago
  18. SCOPUS
  19. Science Citation Index Expanded (SciSearch)
  20. TD Net Discovery Service
  21. UGC-CARE List (India)
Copyright information

Rights and permissions

Springer policies

© Controlled Release Society